Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
YES, great news! Glad I stuck around
Looks like the merger has been approved.
http://www.phlx.com/TraderNews.aspx?id=ETA2016-95
SVACF one for 40 reverse split effective May 2,2016:
http://otce.finra.org/DLSymbolNameChanges
Announced the R/S today. Between that and the VBI meeting date set for next week it sounds like the merger is getting close.
tic - toc ... one more week ... will be interesting to watch
SVACF, VBI meeting set for May 5, 2016! Finally a date. They must be ready. imo.
"You are cordially invited to attend a Special Meeting of the stockholders of VBI Vaccines Inc., a Delaware corporation (referred to as
“VBI,” “we,” “our” or “us”), which we will hold on May 5 , 2016, at 222 Third Street, Suite 2241, Cambridge, Massachusetts 02142 , at 10:00
a.m. , local time"
http://content.stockpr.com/sec/0001493152-16-008729/0001493152-16-008729.pdf
I believe it will be just like COCP, a closing when no one is expecting.
Has anyone contacted the company to find out why it's taking so long? They should have put a PR telling us the exact date of the merger.
"Pursuant to the merger agreement, SciVac and VBI currently expect to complete the merger in the second quarter of 2016" Pg. 116. Guess it is taking a little longer than expected to get everything filed. This document just came out with this info.
http://content.stockpr.com/sec/0001493152-16-008288/0001493152-16-008288.pdf
Agree. The price broke the 50-day MA so that's a very good sign.
My thoughts exactly and I have been averaging down, including buying VBIV. There is too much interest and money involved by OPKo in this one not to see any positive movement. I am curious though why they decided to remove the new financing condition from the closing obligations. Could be both good and bad. Any thoughts?
Think that recall news and no news has brought this one down. See recall is cleared up and merger is pending. Betting on this one is a sleeper that will take off soon after merger.
SVACF appears to be a lost cause until after the merger and R/S
I never saw it hit below .12 today, but it states Trading range for SVACF today is .10 -.13 cents. What's missing here? I would have picked up 65,000 shares below .12.
In today.
Barry Honig 13G filed. Frost cling on, but his timing is good.
http://www.sec.gov/Archives/edgar/data/764195/000141588915003960/honigsc13g_nov2015.htm
Only what the Co has told us. Before April 2016. Hopefully when the voting circulars come out it may have more insight on the closing date, R/S and whether SciVac or VBIV will be raising the 25 million to the table to complete the merger. Considering the post merger OS has already been given at 1.4 billion they mentioned nothing of additional shares for a fund raiser. My guess is they got $$ from SciVac's recent DNAEs deal with OPK! Can't really say without having this quarter's 10Q released yet. All imo
You've gotten your wish. Has any date been given for the merger ( SVACF & VBIV)?
Nice open on SVACF. Looks like it could run if $0.149s take off. JMO.
Thanks and noted
This is just a dumb comment by you. Traders are playing the arbitrage now by buying VBIV and selling SVACF. You get 20.83 shares of SVACF for every share you own of VBIV. The combined Company will do a reverse stock split after the merger and I'm betting that Frost will provide a huge chunk of financing that they said they're raising. I am buying now and after the merger.
If you knew anything about m&a, you would know that these parasite law firms sue every company undergoing a merger (no matter what exchange they are trading on or what stock price). Shareholders never benefit but they settle with the Company for $100k-$250k (sometimes more depending on the size of the merger) and get about 1/3 of that as their fee. Great business model. Don't produce or provide any value and get large fees every time.
Btw, I'm a lawyer, but do transnational work, so I deal with this all the time.
I've been doing this over 15 years with good companies that are about to merge. And it's been working real fine for me (in an Up or Down Market). Thanks anyway for your opinion! LLAP!
Thanks for the information. I am just planning on watching this for a while.
Only a fool frost groupie would buy now
Let them merge then knock yourself out
There are other factors to consider when buying VBIV at its current price. You must consult your Tax Advisor. "If it seems too good to be true, it probably is".I prefer to start buying SVACF at this price, and buy more if price drops, and after the RS. I'm long.
Am I confused or if I bought VBIV at the current price I would be getting SciVac for about 12 cents per share?
I know after the merger SVACF & VBIV will be one. But, for some reason I prefer buying SVACF shares now than VBIV. I think it's because Dr. Frost is already in SVACF. I trust Dr. Frost.
Basic math
You own stock trading at $2.56 or so
You end up getting shares in a company worth 13 cents a share
Good deal?
No wonder shareholders are going to attorneys in droves
Don't invest on emotion
Frost doesn't know you exist
Unless you are an insider how would you know if securities fraud is not involved? You don't. I won't touch this until all that is cleared up. After previous reverse merger this price has only dropped. Enjoying your losses? I will be back with cash to put into vbvi after you guys can pay for the teething problems! Haha
Exactly, this is what I was trying to say to him. Spreading baseless fears.
This happens with every merger/buyout. Are you guys new to trading ? Nice try though... A for effort !!!
What investigation? Link. Or do you mean these parasite plaintiff firms trying to make a quick buck at the expense of the shareholders?
Vbi is under investigation
Thanks Citrati. I'll check it out. My analysis is a 1:100 rs UNLESS VBI is in trouble and on their way out. Haven't had a chance to fully dd them yet. But it just makes sense that VBI would want to keep their listing. So this could be very interesting indeed.
Boo, make sure to read this....https://stocksthatdouble.com/investor-alert/?gclid=CNHl_dyo6MgCFQUHaQodcZQHBg
I am gonna guess r/s, uplist, strong move is very likely.
Looks like Frost may have baited the shorts. imo
I sure would love to know How low can SVACF go for me to grab 100,000 shares at the cheapest price. I love the merger bet SVACF & VBIV, but hate the OS count after the merger.
Is this stock a short term hold or long term hold
lol no worries. SciVac is unlimited.
10.
SHARE CAPITAL
Authorized
Unlimited number of common shares without par value.
http://www.sec.gov/Archives/edgar/data/764195/000147793215004061/levon_20f.htm
I can certainly tell when I don't do my DD.
This was really just a gamble position anyway. Does make me wonder about VBI though.
each share of VBI common stock will be converted into the right to receive 20.808356 common shares of SciVac (the “Exchange Ratio”).
that brings a 2.70 price to our .13
unless i'm really missing something.
http://www.sec.gov/Archives/edgar/data/764195/000149315215005008/ex99-2.htm
And we'll be changing our name to VBI as well. Interesting. Just need to make it back over 2.70 some day.
VBI stockholders will receive approximately 541,573,712 common shares of SciVac, representing approximately 42% of the issued and outstanding shares and voting power of the combined company after giving effect to the Merger.
Wow. I hope I'm reading something wrong.
Total issued and outstanding Common Shares as at Record Date: 756,599,439
http://www.sec.gov/Archives/edgar/data/764195/000149315215004613/ex99-1.htm
SVACF and OPK new license hidden in todays news
Hidden around page 78 is this news
At or prior to the Effective Time, SciVac shall enter into a license agreement (the “DNASE License”) with OPKO Health, Inc. or an Affiliate thereof (“Licensee”), pursuant to which SciVac shall grant Licensee an exclusive license in respect of the Licensed Technology and the Licensed Patents to research, develop, manufacture, use, sell, offer for sale, import, export and distribute Products on substantially identical terms to those granted to SciVac under the CLS License; provided, that the DNASE License shall additionally provide for (i) the transfer by SciVac to Licensee of (x) all data possessed by SciVac in respect of the Licensed Technology and (y) the active pharmaceutical ingredient in respect of the Licensed Technology and (ii) the payment by Licensee to SciVac of a royalty equal to one percent of net sales of any Products. Capitalized terms used in this Section 4.30 and not defined herein shall have the respective meanings ascribed thereto in the CLS License.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10968258
Whats everyone's price projection once the merger happens
Frost made another GREAT merger deal. VBIV is a solid little company with great R&D. They will infuse this with capital, uplift and this will shadow OPKO until it is taken over by OPKO or sold to a bigger Pharma.
SVACF announces big news this morning. The company has entered into an agreement to acquire NASDAQ company VBIV. Under which SciVac has agreed to acquire VBI to form a commercial-stage company with a licensed hepatitis B (“HBV”) vaccine and a pipeline of preventative and therapeutic vaccine candidates. http://yhoo.it/1WdDRsi
Yeah seems to be a little bit of resistance at $0.17 but once these go it doesn’t seem like theres much there to stop this from running to $0.245 in my opinion
Slight wall there
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
243
|
Created
|
06/04/15
|
Type
|
Free
|
Moderators |
NEW YORK, NY / ACCESSWIRE / March 20, 2015 / On September 11 last year, a little-known Israeli financial magazine called Globes came out with a report that Dr. Phillip Frost, Chairman and CEO of Opko Health (NYSE:OPK), and then Chairman of Teva Pharmaceuticals (NYSE:TEVA), was interested in moving a private Israeli biotech called SciVac, 45% owned by Opko, into a corporate shell and making it public.
Today, Frost accomplished his goal, as SciVac has been officially acquired by Levon Resources (OTCMKTS:LVNVF), with 68.4% of the new company going to the former private SciVac shareholders and 31.6% going to former Levon shareholders. Since Opko already has a 45% stake in SciVac, that brings its total take in SciVac to 30.8%.
The deal still has to be voted on by current Levon shareholders in April, but is expected to pass.
Opko has had some success taking stakes in biotech companies so far this year. Its recent 8% stake in Cocrystal Pharma (OTCBB:COCP) has jumped 100% since February. Cocrystal is its second largest investment behind private Russian biotech Pharmsynthez.
SciVac's Hepatitis B Vaccine
SciVac is the developer of a third generation hepatitis B vaccine (HBV) called Sci-B-Vac . It is approved in several countries including SciVac's home country of Israel, where it is administered to hundreds of thousands of newborns each year. While first generation HBV vaccines are mostly effective, their effectiveness is still only 90%. In a clinical trial of over 5,000 people, Sci-B-Vac was shown to have an effectiveness of greater than 98% with higher immunogenicity, or immune response in terms of antibodies produced.
The difference between Sci-B-Vac and the current standard-of-care HBV vaccine is that Sci-B-Vac is derived from mammalian cells instead of yeast cells, and carries on it the three main HBV surface antigens instead of just one. It is believed that the 10% of people who do not respond to first generation HBV vaccines are infected with mutant versions of HBV that escape the single antigen vaccine. It is much harder for HBV to mutate all three surface antigens simultaneously to escape Sci-B-Vac.
Despite vaccines available, HBV is still a huge pandemic. According to the World Health Organization, one third of the world's population is infected with HBV, with up to 400M people suffering chronic infections leading to chronic liver disease. 250M of those people are in the Asia-Pacific region alone.
SciVac's next regulatory goal is approval in the United States, where 12M people are infected every year despite the current first generation vaccine available. What regulatory hurdles have to be overcome remains to be seen, given that Sci-B-Vac is already clinically tested and approved in several countries. SciVac will be aiming at the immunocompromised as well as end stage renal disease and HIV patients, as these are patient populations who have special difficulties responding to current HBV vaccines.
Context of Frost's Latest Move Hints at Possible Future Moves
Dr. Frost's latest move comes in the context of several other interesting stock movements that may tip off future deals in the making. In October last year, only one month after Globes reported Frost's interest in taking SciVac public, Levon acquired 35M shares, or 10% of Pershing Gold Corporation, another one of Frost's pet projects of which he has a 15% stake translating to 53.7M shares. Those 35M shares of PGLC will be moving to new entity Spinco, so speculators looking out for the next Frost-related deal should keep an eye on a possible merger between Spinco and Pershing. A similar deal was inked bewteen Pershing and Continental Resources Group in February 2013 where the latter was acquired by Pershing. Continental had a substantial stake in Pershing at the time.
Cocrystal, which is fairly similar to SciVac in that it is focusing on molecularly tailored vaccines, primarily hepatitis C. Cocrystal is also 22% owned by Frost through his investment trust as well as an 8% stake through Opko. Cocrystal has skyrocketed over 100% since February but lacking any obvious catalyst for doing so. Another possible move to watch then is for a deal between Levon, now SciVac, and Cocrystal, which itself was once BioZone, also an Opko investment that was merged into Cocrystal.
With Frost's myriad of moves and deals over the last few years things can get admittedly confusing and make your head spin. The structure of these mergers, however, repeatedly seems to start with Opko at the base and then moves out from there. Opko itself has been on a nearly 100% tear since December. As for Cocrystal's recent 100% move, it may have investors scratching their heads but connecting the dots here could point to the beginning stages of a Frost deal at some point between Cocrystal and SciVac as both specialize in hepatitis vaccines, as well as one between Spinco and Pershing.
Call it equity consolidation with synergies in mind, it certainly is a fascinating chess game.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |